Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (16)

2024

  1. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

2021

  1. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

    Blood, Vol. 137, Núm. 14, pp. 1879-1894

  2. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  3. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials

    Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538

2019

  1. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 547-555

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications

    Cytometry Part B - Clinical Cytometry, Vol. 92, Núm. 5, pp. 361-370

2016

  1. A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis

    Rheumatology (United Kingdom), Vol. 55, Núm. 6, pp. 1106-1111

  2. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

    Oncotarget, Vol. 7, Núm. 9, pp. 10174-10181

  3. Identification of IRX1 as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 68, Núm. 6, pp. 1384-1391

  4. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2014

  1. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

    Blood, Vol. 123, Núm. 12, pp. 1864-1869

2013

  1. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300

    Gut, Vol. 62, Núm. 10, pp. 1440-1445

  2. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis

    Leukemia, Vol. 27, Núm. 11, pp. 2149-2156

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

2009

  1. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease

    International Journal of Cancer, Vol. 124, Núm. 2, pp. 367-375